Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute Myocardial Infarctio
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0006114
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 105
Patients who received successful percutaneous angioplasty using DES or DCB for the causative lesion
(the criterion for successful angioplasty was defined as the case where the target coronary artery TMI III blood flow and residual lesion stenosis were less than 30%).
1) Ongoing end-stage heart failure or symptoms of heart failure (Killip class II or higher or left ventricular ejection rate <20% on echocardiography)
2) Patients with uncontrolled ischemia such as repetitive pain or repetitive ischemic electrocardiogram changes
3) Patients with uncontrolled ventricular arrhythmia
4) Symptoms of malignant tumors in which myocardial infarction treatment is clinically insignificant
5) Signs of a serious infectious disease
6) Pregnant or lactating patients
7) Participants in other clinical studies who disallow stem cell treatment for myocardial infarction (this treatment can be implemented if the patient voluntarily withdraws consent from other clinical studies)
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eft ventricular ejection rate and wall motion score index measured by echocardiography
- Secondary Outcome Measures
Name Time Method MACE: death, revascularization of target lesions, readmission, changes in BNP, evaluated by SPECT left ventricular ejection rate and wall motion score index, 6-minute walking ability test results